Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical Cure

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Vivax Malaria
Interventions
DRUG

Primaquine

After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites

DRUG

Artesunate

All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites

Trial Locations (1)

Unknown

Institut Pasteur du Cambodge, Phnom Penh

All Listed Sponsors
collaborator

National Centre for Parasitology, Entomology and Malaria Control, Cambodia

OTHER

collaborator

Institut Pasteur du Cambodge

OTHER

lead

University of Maryland, Baltimore

OTHER